Novel Therapeutic Strategies in the Treatment of Systemic Sclerosis

Author:

Gumkowska-Sroka Olga12,Kotyla Kacper2,Mojs Ewa3,Palka Klaudia2,Kotyla Przemysław12ORCID

Affiliation:

1. Department of Rheumatology and Clinical Immunology, Voivodeship Hospital No. 5 in Sosnowiec, Medical University of Silesia, 40-055 Katowice, Poland

2. Department of Internal Medicine Rheumatology and Clinical Immunology, Medical University of Silesia, 40-055 Katowice, Poland

3. Department of Clinical Psychology, Poznan University of Medical Sciences, 61-701 Poznan, Poland

Abstract

Systemic sclerosis is a connective tissue disease of unknown origin and with an unpredictable course, with both cutaneous and internal organ manifestations. Despite the enormous progress in rheumatology and clinical immunology, the background of this disease is largely unknown, and no specific therapy exists. The therapeutic approach aims to treat and preserve the function of internal organs, and this approach is commonly referred to as organ-based treatment. However, in modern times, data from other branches of medicine may offer insight into how to treat disease-related complications, making it possible to find new drugs to treat this disease. In this review, we present therapeutic options aiming to stop the progression of fibrotic processes, restore the aberrant immune response, stop improper signalling from proinflammatory cytokines, and halt the production of disease-related autoantibodies.

Funder

Medical University of Silesia, Katowice, Poland

Publisher

MDPI AG

Subject

Drug Discovery,Pharmaceutical Science,Molecular Medicine

Reference144 articles.

1. Pathophysiology of systemic sclerosis (scleroderma);Rosendahl;Kaohsiung J. Med. Sci.,2022

2. Epidemiology of systemic sclerosis and systemic sclerosis-associated interstitial lung disease;Bergamasco;Clin. Epidemiol.,2019

3. Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis;LeRoy;J. Rheumatol.,1988

4. Autoantibodies in systemic sclerosis;Mehra;Autoimmun. Rev.,2013

5. Update on autoantibodies in systemic sclerosis;Walker;Curr. Opin. Rheumatol.,2007

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3